Cognito’s Alzheimer’s brainwave
Gamma frequency neuromodulation is the key to treating dementia, according to the MIT spinout.
Point’s path leads to a Spac
The radiopharmaceutical researcher was negotiating a series B funding round when it got an offer from a Spac that it could not refuse.
A Spac makes it happen for 4D Pharma
The boom in blank-cheque companies could offer small UK developers a new route to a US stock market listing.
Onduo takes its time
The Verily subsidiary has the luxury of patient backers. But hungrier rivals could steal a march.
Can we freeze them? Yes we can, says Nkarta
The company is now in the clinic, claiming to have cleared one of the biggest hurdles blocking development of an NK cell therapy.
Bayer’s gene therapy juggling act
Two arm’s-length acquisitions and two licensing deals have given Bayer a cell and gene therapy unit; now to bring it all together.
Apellis takes the complement fight to Astrazeneca
The smaller company believes that its complement C3 inhibitor could make Soliris and Ultomiris redundant in PNH.
Kinaset takes a sledgehammer to an asthma conundrum
The nascent company hopes to prove that its inhaled pan-Jak is best in class.
